Cargando…

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer

Patients were identified from a population-based prospective study of 4990 individuals with symptoms associated with colorectal cancer (CRC). A total of 244 CRC tissue samples were available for immunohistochemical staining of uPAR, semiquantitatively scored at the invasive front, and in the tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Illemann, Martin, Laerum, Ole Didrik, Hasselby, Jane Preuss, Thurison, Tine, Høyer-Hansen, Gunilla, Nielsen, Hans Jørgen, Christensen, Ib Jarle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303153/ https://www.ncbi.nlm.nih.gov/pubmed/24889870 http://dx.doi.org/10.1002/cam4.242

Ejemplares similares

uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder – Possible Clinical Implications
por: Dohn, Line Hammer, et al.
Publicado: (2015)

Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
por: Alpízar-Alpízar, Warner, et al.
Publicado: (2020)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder
por: Dohn, Line H., et al.
Publicado: (2021)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
por: Mauro, Concetta Di, et al.
Publicado: (2017)

First-in-human uPAR PET: Imaging of Cancer Aggressiveness
por: Persson, Morten, et al.
Publicado: (2015)

Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR)
por: Ye, Yao, et al.
Publicado: (2020)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
por: Margheri, Francesca, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives
por: Skovgaard, Dorthe, et al.
Publicado: (2016)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
por: Zhao, Baoyu, et al.
Publicado: (2015)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
por: Shmakova, Anna A., et al.
Publicado: (2022)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention
por: Leth, Julie Maja, et al.
Publicado: (2021)

Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2022)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma
por: Semina, Ekaterina V., et al.
Publicado: (2020)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
por: Sharma, Shailza, et al.
Publicado: (2021)

Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group
por: Sorio, Claudio, et al.
Publicado: (2011)

Author Correction: Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2023)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
por: Christensen, Anders, et al.
Publicado: (2017)

The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells
por: Lejeune, Danielle, et al.
Publicado: (2006)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

Integrin is on uPAR to unleash cells
por: LeBrasseur, Nicole
Publicado: (2003)

uPAR's signaling two step
por: Leslie, Mitch
Publicado: (2007)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
por: Harel, Efrat T., et al.
Publicado: (2019)

Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR)
por: Elhussieny, Ahmed, et al.
Publicado: (2021)

Histopathological Growth Pattern, Proteolysis and Angiogenesis in Chemonaive Patients Resected for Multiple Colorectal Liver Metastases
por: Eefsen, Rikke Løvendahl, et al.
Publicado: (2012)

Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs
por: Chang, Yu-Ching, et al.
Publicado: (2023)

uPAR: An Essential Factor for Tumor Development
por: Lv, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3p54llcoalg2dm9vd8382q4spf